drugset / Trial / NCT00099021

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

NCT00099021

Phase 2 Completed 21 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be effective in preventing head and neck cancer.

Timeline

Start
2003-06
Primary completion
2008-06-27
Completion
2008-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule Oral